An interventional study of CARLEN System in Mitral Regurgitation Functional, sponsored by Nyra Medical, Inc.. Recruiting at 3 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Nyra Medical, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Mitral Valve Insufficiency with a site in United States — 33 open to participants now, 53 under way, none of them phase 3. Mitral Valve Insufficiency · United States.
Among the 118 studies in Mitral Valve Insufficiency with a site in United States, this one is the 52nd largest by planned enrollment of the 81 interventional ones that give a count, is one of 10 that started in 2026, is one of 64 with no phase, reaches primary completion later than 32 of the 52 other live ones, and was the 113th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →33 of the 118 studies in Mitral Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Capstan Medical · Sites in United States
Ages 18+
Abbott Medical Devices · Sites in United States
Ages 18+
Polares Medical SA · Sites in United States
Ages 21+
InnovHeart · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 4 · Phase 4 4
First in 1992; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 69 across 280 interventional studies indexed under Mitral Valve Insufficiency.
Median enrollment 60 across the 81 interventional studies, 200 across the 37 observational. Of the 52 that completed or were terminated, 26 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 118 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Nyra Medical, Inc. as lead sponsor.
Nyra Medical, Inc. has 1 study filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
13 of the studies in Mitral Valve Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04408430Mayra GuerreroThe MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves). | 2026-12 |
| NCT07655505Intuitive SurgicalUse of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair | 2026-12-31 |
| NCT05061004Abbott Medical DevicesCephea Early Feasibility Study | 2026-12-31 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT06738615Atlantic Health SystemAssessing the Relationship Between Symptoms and Mitral Regurgitnant. Severity | 2027-01-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 118 studies in Mitral Valve Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Safety and performance evaluation of the CARLEN System in patients with functional mitral valve regurgitation.
The purpose of this early feasibility study (EFS) is to evaluate the safety and performance of the CARLEN System in patients with symptomatic, moderate-to-severe or severe (MR ≥ 3+), functional (or secondary) mitral regurgitation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CARLEN System
Device: CARLEN System
CARLEN System
Primary Endpoint
Freedom from device- or procedure-related serious adverse events through 30-days post-procedure
Time frame: 30-days post-procedure
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.
Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 17 months is below that.
Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.